Kolon Life Science KRX:102940KOSDAQ
코오롱생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Kolon Life Science reported revenue of ₩50.6bn, down 4.5% year on year, and an operating loss of ₩785m. Kolon Life Science (코오롱생명과학) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Kolon Life Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩50.6bn | -4.5% | −₩785m | −₩2.2bn |
| Q1 2026 | ₩49.7bn | +10.8% | ₩2.9bn | ₩20.8bn |
| Q4 2025 derived | ₩44.7bn | -4.6% | −₩2.7bn | −₩9.6bn |
| Q3 2025 | ₩66.5bn | +85.1% | ₩18.9bn | ₩25.5bn |
| Q2 2025 | ₩53.0bn | +32.2% | ₩1.3bn | −₩1.5bn |
| Q1 2025 | ₩44.8bn | +16.3% | ₩74m | ₩10.5bn |
| Q4 2024 derived | ₩46.9bn | +40.1% | −₩3.2bn | −₩16.7bn |
| Q3 2024 | ₩35.9bn | +27.3% | −₩9.0bn | −₩12.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Kolon Life Science top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Kolon Life Science news Korean headlines
No articles yet.